Earlier today Edwards LifeScience and Medtronic agreed to a global settlement of the litigation over Edwards' transcatheter heart valve technology. Medtronic will pay $750 million upfront, with ongoing royalties through April 2022. Wall Street Journal story here, Forbes here, Reuters here. This should be the end of the litigation I reported on last month here and here.
Post a Comment